高聚生联合化疗治疗结肠癌的近期疗效观察

目的:观察高聚生联合化疗对结肠癌患者的肌体免疫调节作用。方法:68例结肠癌患者随机分为单纯化疗组和高聚生联合化疗组,单纯化疗组用奥沙利铂 亚叶酸钙 5-氟脲嘧啶持续静脉点滴方案,联合组在此基础上静脉点滴高聚生。化疗3个周期(9周)后复查CT评价疗效。结果:联合组的近期疗效高于单纯化疗组,具统计学差异(P<0.05);单纯化疗组患者经化疗后CD3 值较化疗前明显升高,而CD4 值及CD4 /CD8 比值较化疗前明显降低(P<0.05〉;化疗联合高聚生治疗组患者化疗前后的CD3 、CD4 值及CD4 /CD8 比值无显著差异;联合组的主要不良反应为发热和局部静脉炎。结论:高聚生联合化疗能克服化疗对机体的免疫抑制作用,提高结肠癌治疗的有效率。

Clinical Study on Colon Cancer Treated with Chemotherapy Combined with Highly Agglomerative Staphylococcin(HAS)

Objective:To evaluate the efficacy of chemotherapy combined with highly agglomerative staphylococcin(HAS)for colon cancer.Methods:68 cases were randomized to receive chemotherapy combined with HAS(group A)and chemotherapy alone(group B).Oxaliplatin combined with FOLFOX4 was both used in two groups,and HAS was only used in group A.Results:The effect rate of group A Was higher than group B after 3 cycles(6 weeks)chemotherapy(P<0.05).Before chemotherapy in group B,CD3 was much higher,CD4 and CD4 /CD8 were obviously lower than those after chemotherapy(P<0.05).CD3 ,CD4 and CD4 /CD8 had no significant difference before and after chemotherapy in group A.The major side effects were fever and phlebitis.Conclusion:HAS can reduce the immunosuppressive action caused by chemotherapy and enhance curative effect of colon cancer.